Prevention of Insomnia Using a Stepped Care Model in Adults

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06156293
Collaborator
(none)
1,016
1
2
29.5
34.4

Study Details

Study Description

Brief Summary

Insomnia is one of the most common sleep disorders and affects approximately 10 - 40% of the population across different age groups in Hong Kong. Our previous study has shown that insomnia can be prevented through a brief cognitive behavioral prevention program in adolescents. However, there is very limited data in the adult population.

Current study aims to evaluate a digital sleep-focused platform which consists of different intervention plan according to user's insomnia severity level and employed a stepped care model. Thus, the effectiveness of the stepped care model will be evaluated in a real world setting using stepped wedge cluster randomized controlled design to evaluate potential preventive effect on adults who only with mild insomnia symptoms. The program will be rolled out to different districts in Hong Kong sequentially in 18 districts over 4 steps with a equally spaced time periods. The primary aim of this study is to evaluate the effects of a stepped-care CBT-I model in improving sleep and prevent the incidence of insomnia among participants with mild insomnia.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive behavioral prevention program for insomnia (CBP-I)
N/A

Detailed Description

This interventional study will be a multicenter, assessor-blinded, pragmatic stepped-wedge cluster randomized controlled trial. A total of 18 districts will be included in the study and the randomization will be carried out based on the districts. The stepped-care CBT-I intervention will be sequentially rolled out to the 4-6 districts per step according to a computer-generated random number while the remaining clusters will continue to stay unexposed to the CBT-I intervention over the control period. Therefore after 4-step exposure, all clusters will receive the stepped-care CBT-I intervention. A total of 3 follow-up assessments (post intervention, 3-month and 12-month follow up) will be conducted to assess the effectiveness and long-term effects of the stepped care model.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1016 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Pragmatic stepped wedge design - over 4 months, 18 sites enter trial at 1 month intervals.Pragmatic stepped wedge design - over 4 months, 18 sites enter trial at 1 month intervals.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Prevention of Insomnia Using a Stepped Care Model in Adults: a Pragmatic Stepped-wedge Cluster Randomized Trial
Anticipated Study Start Date :
Dec 15, 2023
Anticipated Primary Completion Date :
Dec 15, 2025
Anticipated Study Completion Date :
Jun 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stepped-care CBT-I group

A total of 3 steps of sleep focused intervention will be provided, with the objectives to increase the awareness of sleep health, increase sleep literacy, establish good sleep hygiene and treat insomnia. Step 1: self-help digital sleep focused program; Step 2: guided intervention; Step 3: individualized consultation.

Behavioral: Cognitive behavioral prevention program for insomnia (CBP-I)
CBP-I will be provided to participants once their districts are exposed.

No Intervention: Control group

Participants in the control group remain unexposed to the stepped-care sleep-focused intervention.

Outcome Measures

Primary Outcome Measures

  1. Insomnia severity index [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month postintervention and 12-month post-intervention follow up]

    The primary outcome will be the perceived insomnia severity measured by Insomnia Severity Index (ISI).

Secondary Outcome Measures

  1. Severity of depression [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    Patient Health Questionnaire-9 (PHQ-9) will be used to measure the severity of depression.

  2. Severity of anxiety [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    General Anxiety Disorder-7 (GAD-7) will be used to measure the severity of anxiety.

  3. Health-related quality of life [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    The health-related quality of life (HRQoL) will be measured by the EuroQol-5D (EQ).

  4. Chronic insomnia diagnosis [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    A checklist based on Diagnostic and statistical manual of mental disorders will be implemented to measure the incidence of chronic insomnia.

  5. Medication usage [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    A checklist will be used to measure the subject's medication usage change.

  6. Clinical global impression [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    Clinical Global Impression (CGI) will be used to assess the insomnia severity over time.

  7. Patient-report clinical global impression [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    A single-item CGI will be used to ask the participant whether they experience sleep improvement or change over the past week or not.

  8. Sleep duration [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    Two self-report questions will be used to record the sleep duration during weekdays and weekends of the participants.

  9. Subjective sleep as measured by sleep diary [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    Self-report sleep diary will be used to record subjective sleep of the participants including total time in bed, sleep onset latency, total sleep duration, sleep efficiency and wake after sleep onset.

  10. Healthcare resource use [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    The use and expense of sleep-promoting medication, psychotherapy, and other complementary treatments for sleep improvement will be collected from individual participants using a self-developed questionnaire, with a focus on their healthcare resource utilization.

  11. Work and social functioning [Post-intervention (ranging from 8 weeks to 24 weeks, depending on the treatment level), 3-month post-intervention and 12-month post-intervention follow up]

    A 5-item questionnaire developed from Work and Social Adjustment Scale (WSAS) will be used to measure the daytime functioning of the participants such as ability to work, home management, social and private leisure activities, and close relationship maintenance

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Chinese adults aged 18-70 years old,

  2. The score of Insomnia Severity Index < 10.

Exclusion Criteria:
  1. present with psychotic disorders such as bipolar disorder and schizophrenia,

  2. present with severe depression or suicidal ideation,

  3. present with neurodegenerative diseases that prevent participant from completing the intervention (e.g., dementia and Parkinson's disease).

  4. unable to provide consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Psychiatry, the Chinese University of Hong Kong Hong Kong China

Sponsors and Collaborators

  • Chinese University of Hong Kong

Investigators

  • Principal Investigator: Yun Kwok Wing, FRCPsych, Department of Psychiatry, the Chinese University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CHAN NGAN YIN, Assistant Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT06156293
Other Study ID Numbers:
  • 20230816.02
First Posted:
Dec 5, 2023
Last Update Posted:
Dec 5, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by CHAN NGAN YIN, Assistant Professor, Chinese University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 5, 2023